Skip to main content
OpenTrials
Completed

NCT Number: NCT03437811

Airway Clearance System (K031876) Phase IV Device Efficacy

Phase IV interventional study of adults (18 to 55) having a diagnosis of cystic fibrosis (mild, moderate or severe). The study is completely voluntary and is designed to measure participants use and the effectiveness of the device within the 510K indication of: airway clearance therapy when external manipulation of the thorax. The trial period shall be 21 days and include use of a FDA cleared pulse oximetry monitor (K131111), manual spirometer as well as completion of semi-weekly participant survey.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

MED Systems, Inc.

San Diego, California, 92117, United States

About this study

Phase IV interventional study, of participants with cystic fibrosis with mild, moderate or severe conditions, for the efficacy of the Electro Flo Percussor, Model 5000 (K031876), Regulation Number: 21 CFR 868.5665, with current FDA indication of: provide airway clearance therapy when external manipulation of the thorax is the physician's choice of treatment. Indications for this form of therapy are described by the American Association for Respiratory Care (AARC) in the Clinical Practices Guidelines for Postural Drainage Therapy ( I ) (1991). According to AARC guidelines, specific indications for external manipulation of the thorax include evidence or a suggestion of retained secretions, evidence that the patient is having difficulty with the secretion clearance, or presence of atelectasis caused by mucus plugging. In addition, the Med Systems Electro Flo Percussor Model 5000 is also indicated for external manipulation of the thorax to promote airway clearance or improve bronchial drainage for purposes of collecting mucus for diagnostic evaluation.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Previously diagnosed with cystic fibrosis (mild, moderate or severe)
  • Prescribed (licensed medical provider) airway clearance device/system for at home, self-treatment for airway clearance
  • Physically able to perform self-treatment or treatment by an at home medical provider

Exclusion criteria

  • History of tobacco use
  • History of excessive alcohol consumption, more than 2 drinks per day, 10 per week
  • Any other medical condition that would preclude use of an airway clearance device
  • Previously diagnosed with major cardiological disease

Treatment and study plan

Electro Flo Percussor, Model 5000

Device

FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1

Primary outcomes

  1. Percentage change of oxygen levels in the blood (pulse oximetry).

    Time frame: Change from baseline up to 3.5 hours.

    SpO2 will be monitored using the standard pulse oximeter system (K131111).

Secondary outcomes

  1. Percentage change of lung function

    Time frame: Change from baseline up to 3.5 hours

    Evaluate expiratory forced vital capacity (FVC) and forced expiratory volume (FEV1) will be monitored with standard spirometer.

Sponsors and collaborators

Lead sponsor

Mack Biotech, Corp.

Industry

Registry information

Official study title

Efficacy of Med Systems' Electro Flo Percussor Model 5000, Airway Clearance System, for Pulmonary Clearance of Secretions.

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Feb 19, 2018
Registry last updated
Apr 10, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.